Brief: Trevi Therapeutics Provides Update On Haduvio's Clinical Development Program
03/10/2024 21:39
Trevi Therapeutics Inc TRVI.O :
* TREVI THERAPEUTICS PROVIDES UPDATE ON HADUVIO'S CLINICAL
DEVELOPMENT PROGRAM
* TREVI THERAPEUTICS INC: HUMAN ABUSE POTENTIAL (HAP) STUDY
DOSING
COMPLETE; TOPLINE RESULTS EXPECTED IN DECEMBER 2024
* TREVI THERAPEUTICS INC: SAMPLE SIZE RE-ESTIMATION RESULTS
EXPECTED IN DEC 2024 FOR PHASE 2B CORAL TRIAL
Source text for Eikon: ID:nPn1FlJ9Va
Further company coverage: TRVI.O
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million